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There are no standardised clinical guidelines for the management of Parkinson’s disease during 
pregnancy. Increasing maternal age would suggest that the incidence of pregnancy in women 
diagnosed with Parkinson’s disease is likely to increase. 
 
Objective 
To evaluate the evidence for the treatment of Parkinson’s disease during pregnancy, and to canvass 
opinion from patients and clinical teams as to the optimum clinical management in this setting. 
 
Methods 
This involved: i) a literature review of available evidence for the use of oral medical therapy for the 
management of PD during pregnancy, and ii) anonymised survey of patients and clinical teams 
relating to previous clinical experiences.  
 
Results 
Literature review identified 31 publications (148 pregnancies; 49 Parkinson’s Disease, 2 
Parkinsonism, 21 Dopa-Responsive Dystonia, 32 Restless Leg Syndrome, 1 Schizophrenia and 43 
unknown indication) detailing treatment with levodopa, and 12 publications with dopamine 
agonists.  Adverse outcomes included seizures and congenital malformations. Survey participation 
included patients (n=7), neurologists (n=35), PD Nurse Specialists (n=50), obstetricians (n=15) and 
midwives (n=20) and identified a further 34 cases of pregnancy in women with PD. Common themes 
for suggested management included: optimisation of motor symptoms, preference for levodopa 
monotherapy, and normal delivery unless indicated by obstetric causes. 
 
Conclusions 
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This study demonstrates the paucity of evidence for decision-making in the medical management of 
PD during pregnancy. Collaboration is needed to develop a prospective registry, with longitudinal 
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Approximately 5% of Parkinson’s Disease (PD) diagnoses are made in individuals <40 years, meaning 
that women with early-onset PD may become pregnant after diagnosis.(1)  The incidence of 
pregnancy in women with PD is unclear, although it is likely to rise given the trend towards 
increasing maternal age and no data to date indicates a reduction in fertility for those women 
diagnosed with PD.(2)  Previous case series have documented foetal and maternal outcomes in 
multiple pregnancies, including adverse events such as spontaneous abortion. However, information 
about the use and safety of medication for the treatment of PD during pregnancy is largely 
anecdotal and lacks long-term follow-up maternal and child outcome data. The lack of evidence-
based practice and standardised clinical guidelines means clinicians and women with PD face 
uncertainty as to how best to plan care during this period. This study seeks to evaluate and 
summarise currently available evidence for the use of dopaminergic therapy during pregnancy, and 




This study includes: i) a structured literature review of available evidence relating to the use of 
medication to treat PD during pregnancy, and ii) a survey of patient and clinical team experiences of 
PD management during pregnancy.  
 
Literature Search 
Our literature review aimed to address the obstetric outcomes when medication used to treat PD 
had been used during pregnancy, and to assess the quality of evidence against GRADE criteria. 
Reports meeting the following criteria were eligible for inclusion; i) those relating to the use of 
levodopa, dopamine agonist, MOA-B or COMT inhibitor, or anti-muscarinic therapy in pregnant 
women, irrespective of diagnosis, ii) an English language abstract, iii) data and observations from 
pregnancy in humans, rather than other mammalian species. To maximise reach, data relating to the 
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use of PD therapies in other dopamine-responsive conditions such as restless leg syndrome and 
dopa-responsive dystonia were also included. No restriction was placed on the date of publication, 
with information sourced using the MEDLINE and Web of Science databases. Additional articles were 
also identified from the reference list of screened articles. The database search strategy is 
summarised in supplementary Figure 1. Those articles included were subsequently divided into case 
reports, small case series (n<5), large case series (n>5), and larger observational studies 
(Supplementary Table 1). Information collated included: name or class of dopaminergic medication, 
number of pregnancies exposed, reason for treatment (maternal diagnosis), and pregnancy 
outcome. The GRADE criteria were used to assess the quality of evidence relating to each 
medication with the summary measure determined by the total number of live births, spontaneous 
abortions, terminations of pregnancy and still births which occurred with the use of each drug.  
 
Survey data collection 
Via an online survey, data were collected on five key domains: i) Medication to treat PD symptoms, 
ii) PD symptoms during pregnancy, iii) Organisation of clinical care, iv) Adverse obstetric events and 
delivery, v) Post-partum period. Informed consent was obtained from five groups: individuals 
diagnosed with PD who had been pregnant since diagnosis, neurologists, obstetricians, midwives 
and PD specialist nurses. The organisations involved in contacting these groups are summarised in 
Supplementary Figure 2. Healthcare professionals without previous clinical experience in this setting 
were also invited to share suggested management plans in order to gain a wider context of opinion.  
 
Data analysis  
Nominal and multiple-choice survey responses were analysed descriptively.  Open text responses 
were coded according to content, and an inductive, data-driven coding approach employed. Content 
analysis identified key themes, and constant comparison enabled a search for emerging themes.  
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Literature Review: Clinical evidence for the use of anti-parkinsonian medication during pregnancy 
Supplementary Table 1 and Table 1 summarise the publications reviewed and outcomes 
respectively.(3,4,13–22,5,23–32,6,33–38,7–12) In brief, 31 publications reported the use of 
levodopa in 148 pregnancies, with examples of reported adverse outcomes including: congenital 
malformation (n=8) and seizures.[4-7] Two publications provided results of genetic testing, including 
a total of four cases with Parkin mutations.(21,22) Of the 109 levodopa-exposed pregnancies for 
which outcomes were available, 83% resulted in live births (n=91), 8% were electively terminated 
(n=9) and 9% resulted in spontaneous abortion (n=10). Fewer publications included use of dopamine 
agonists (n=12), anti-muscarinic medication (n=4), catechol-O-methyl-transferase (COMT) inhibitors 
(n=4), monoamine-oxidase B inhibitors (MOBI) (n=3) and deep brain stimulation (n=4). The largest 
case series of DBS during pregnancy identified 11 individuals with 18 births (PD=3, Dystonia=5, 
Tourette’s Syndrome=2, Obsessive-Compulsive Disorder=1). Of the three cases diagnosed with PD, 
one stopped her medication during pregnancy and resumed at the same dose post-partum, another 
changed from a dopamine agonist to levodopa, and back to a dopamine agonist post-partum, and 
the third continued her treatment of a dopamine agonist and MAOI throughout.(21) None of these 
women breast fed in the post-partum period owing to concerns of the impact of their oral medical 
therapy. The quality of evidence is summarised according to the GRADE criteria (Table 2).  
 
Survey Outcomes: Patients, Neurologists, PD Nurse Specialists, Obstetricians and Midwives 
Our survey identified 34 pregnancies in women with PD, with medication continued in 15, and two 
reported complications (Table 2).  
 
Women diagnosed with PD with subsequent pregnancy 
Seven women completed our survey regarding 10 pregnancies, resulting in eight healthy live births, 
one stillbirth (24 weeks) and one pregnancy with unknown outcome (Table 2). Three women were 
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diagnosed with PD during pregnancy (20-48 years) and three women received oral medical therapy 
during 4 pregnancies. One patient reported an improvement in motor symptoms, despite 
withdrawal of all PD medications during this period.  Two patients (2 and 6) required oral medical 
therapy post-partum due to worsening motor symptoms.  
 
Neurologists  
Thirty-five neurologists responded to our survey, eight of whom had experience caring for women 
with PD during 12 pregnancies (Table 3 and Supplementary Table 2). Management suggestions 
included reviewing medication safety and using as few medications as possible, particularly pre-
conception and during the first trimester. Emphasis was placed on maintaining good motor 
symptom management during pregnancy, and if required, oral levodopa monotherapy was 
preferred. They also suggested regular review, referral to specialist movement disorder clinics during 
the antepartum period and close working with other members of the multi-disciplinary team.  
 
PD Nurse Specialists  
Fifty responses were obtained; five of whom had experience of caring for patients with PD during 
eight pregnancies (Table 3 and Supplementary Table 2). Suggestions focused on the antenatal 
period, including review of medication use and aiming to minimise oral medical therapy. There was 
wide support for adopting a multi-disciplinary approach (n=19). Suggestions for organisation of care 
included open-access to neurology services (n=1) and more frequent monitoring (n=6).  
 
Obstetricians 
Fifteen responses were obtained from obstetricians; two having had experience managing four 
pregnancies in mothers with PD (Table 3 and Supplementary Table 2). Twelve suggested obstetric-
led care due to the unknown medication risk in pregnancy and the potential for worsening motor 
symptoms. There was consensus that a normal schedule of antenatal appointments should be 
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followed, with increased review if problems arose. Additional recommendations included: pre-
pregnancy counselling, monthly joint clinics with the neurology team and co-ordination of antenatal 
appointments with foetal growth scans. None advised delivery by caesarean section, this being 
reserved for obstetric indications only. Suggestions for post-partum management included standard 




Twenty midwives responded to the survey, none of whom had experience of caring for women with 
PD during pregnancy.  Seventeen shared suggestions for pregnancy care (Supplementary Table 3). 
Antenatally, these included: obstetric-led care (n=7), multi-disciplinary team approach (n=8), 
involvement of physiotherapists to aid balance difficulties (n=4) and offering home visits to avoid 
long waits in antenatal clinics (n=2). Active, mobile labour was advised, although the potential for 
women to tire, guided by their experience of other chronic disorders, was highlighted alongside the 




This study represents the first to synthesise evidence relating to clinical outcomes of the 
management of PD during pregnancy and investigate care experiences from patient and multi-
disciplinary team perspectives.  
 
Medication during pregnancy 
Literature review:  
Our literature review demonstrates the paucity of evidence for the safety of dopaminergic therapy 
during pregnancy, with levodopa the preferred form of treatment. Ten pregnancies, from a total of 
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148, resulted in spontaneous abortion (9.2%)  and three live births were associated with foetal 
congenital abnormalities including, patent foramen ovale and ductus arteriosus.(3) Rates of clinically 
recognised pregnancies resulting in foetal loss in the general population are estimated to be 10-24%, 
indicating no excess rate amongst this patient group, and particularly in the context of exposure to 
levodopa therapy.(41)Fewer studies related to the use of dopamine agonists, anti-muscarinics and 
COMT and MOA-B inhibitors during pregnancy, and therefore estimates of foetal loss are more 
difficult to determine. Spontaneous abortion was reported in four cases of pramipexole 
monotherapy.(3,42) 
 
Our literature search also included data relating to the use of medication in the treatment of other 
dopamine-responsive disorders during pregnancy such as Restless Legs Syndrome (RLS) and Dopa-
Responsive Dystonia (DRD). The underlying aetiology of these disorders is distinct from that of PD 
and may independently impact pregnancy irrespective of medication. There was substantial 
variation in the dose of all prescribed medication (Table 1) and understanding of the risk of obstetric 
complications is limited by the majority of evidence provided in the form of case reports. 
Furthermore, PD medications were frequently co-prescribed, making it difficult to elucidate the 
effects of individual drugs. Four publications relating to the use of deep brain stimulation during 23 
pregnancies were also identified (Supplementary Table 1). All operations were undertaken pre-
pregnancy with 23 live births and one spontaneous abortion in the first few weeks of pregnancy 
reported. No complications with the use of DBS during pregnancy were reported.  
 
Multi-disciplinary survey outcomes 
Our survey found 88.2% (n=30/34) of the identified pregnancies resulted in a live birth, and 5.9% 
(n=2/34) ended in spontaneous abortion, below estimated rates in the general population.(41) 
Where medication was continued, there was a preference for levodopa.  However, these results are 
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retrospectively reported, and due to recruitment methods, potentially not representative of the 
spectrum of women diagnosed with PD who have subsequently become pregnant.  
 
Parkinson’s symptoms during pregnancy  
Published literature to date suggests that women experience variation in their PD symptoms during 
pregnancy, with early reports suggesting that 65% of women experienced worsening of their 
symptoms, in spite of the continuation of medical therapy.(12) The physiological mechanisms by 
which pregnancy can result in symptomatic change is poorly understood. Altered pharmacokinetics 
due to the expansion in plasma volume may reduce peak serum concentrations of oral medical 
therapy, while changes to gastrointestinal absorption and increases in eGFR may affect the 
availability and renal elimination of drugs.(43) In keeping with this, our survey identified variation in 
the evolution of motor symptoms during the course of pregnancy, although this may have related to 
a number of factors, including ongoing adjustments to the dose of medical therapy for which no 
serum measurements were available.(1)  
 
Half of the women surveyed noted worsening of symptoms during pregnancy, thirteen reported no 
change and one patient reported an overall improvement in motor symptoms, mood and energy 
levels during two pregnancies. Where symptoms worsened, 60% (n=9) did so after all or adjuvant 
medications were withheld or doses reduced, while 25% (n=4) noted symptom worsening while 
receiving treatment with levodopa monotherapy. Only 15% (n=2) of women whose symptoms 
worsened did so despite no change to PD medications. These reports suggest that although PD 
symptoms during pregnancy are likely to vary between individuals, the maintenance of at least pre-
pregnancy treatment levels is likely to limit symptomatic fluctuation.  
 
Organisation of care 
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Studies of other chronic disorders (e.g. rheumatoid arthritis) in pregnancy emphasise the need for 
well-coordinated multidisciplinary involvement, with decision aids demonstrating enhanced shared 
decision making.(44) In spite of this, there are no currently available guidelines on obstetric best 
practice in the management of PD during pregnancy, and only two patients in this cohort received 
more frequent antenatal neurology input. All of the obstetricians consulted felt that antenatal care 
should be consultant-led and follow a normal schedule of antenatal appointments. Although joint 
obstetric/neurology review was only undertaken in three cases in this study, both clinician groups 
advocated enhanced communication between teams. 
 
Adverse events and delivery   
To date, there is no evidence to suggest higher rates of foetal or maternal complications, fertility 
difficulties or birth related complications in women with PD.(1) Obstetrician responses in this survey 
felt there was no indication to alter the standard of post-partum care (4/15 (27%)) and that a 
diagnosis of PD would not contra-indicate vaginal delivery, suggesting that delivery by caesarean 
section should be reserved for obstetric indications only. Information relating to the mode of 
delivery was available for 12 pregnancies; eight vaginal deliveries, two emergency caesarean 
sections (17%) and two assisted deliveries (17%). The rate of emergency section is ~15% in the UK, 
broadly comparable to that observed in our data set.(45) 
 
Post-partum period, breastfeeding and support 
The challenges facing new mothers with PD are poorly understood, with deteriorating fine motor 
skills often presenting functional difficulties in undertaking daily tasks. Decisions relating to breast-
feeding are complicated by limited information regarding the potential risk of medication to infants, 
although plasma and breastmilk levodopa concentrations in a single study estimated the level of 
exposure to be low (0.016-0.023mg/kg/day).(24) The inhibitory effects of levodopa and dopamine 
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agonists on prolactin synthesis suggests they may suppress lactation, although two women in this 
cohort were able to breastfeed for a limited time. 
 
Conclusion 
This study has collated information from a number of distinct sources, highlighting several key 
aspects. The majority of outcome data for pregnancies of women diagnosed with PD are linked with 
use of levodopa treatment during this period, with outcome data only available in a small number of 
cases for those treated with other forms of dopaminergic therapy. Results from our systematic 
review indicate no excess rate of miscarriage, stillbirth or congenital deformity amongst this patient 
group compared to the general population. Patient and MDT survey responses suggest that an 
optimised care plan would include close co-operation between neurology and obstetric teams 
during pregnancy and delivery. However, the most important element highlighted is the need for an 
international prospective registry for women diagnosed with PD during and after pregnancy, similar 
to those for other chronic neurological disorders. A registry would aid in the development of 
consensus guidelines for clinical care in this setting and provide longer-term follow-up data on infant 
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Supplementary Figure Legends 
Supplementary Figure 1: Schematic representation of the search terms used during the 
systematic literature review. Blue boxes represent the research terms used and number of 
publications identified. Green boxes represent additional publications identified, and orange 
boxes those excluded as not considered relevant to this review. Articles were divided into 
case reports (n=1), smaller case series (n<5), and larger case series or cohort studies (n>5). 
COMT inhibitor: catechol-O-methyl-transferase inhibitor, MAOI: monoamine-oxidase 
inhibitors. 
 
Supplementary Figure 2: Schematic representation or sources of participant recruitment 
from clinical and patient sectors. Green: patient recruitment, Orange: Neurology 
recruitment, Blue: Parkinson’s Disease Nurse Specialist Recruitment, Yellow: Midwifery 
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Table 1: Outcomes following in utero exposure to Parkinson’s medications in the treatment of neuro-psychiatric disorders 
 
In utero exposure to Parkinson’s medication  
No 
pregnancies 




Pregnancy outcome Complications 
In utero exposure to Levodopa 
Case reports: 22 publications  





No data (12) 
6-40 
No data (3) 
31 live births (4 prem) 2 SA Neonate seizure 1 hr post-partum., Placental 
abruption, VSD in 1 twin., PPROM in 2 pregnancies 
Small case series: 3 publications   
12 pregnancies  9 PD, 3 DRD Levodopa 
preparations   
1250-4000 36 No data (9) 10 live births, 2 SA    




14 PD, 14 DRD, 32 
RLS 
1 Psych, No data 
(43) 
 100-400 
No data (52) 
12-36 
No data (52) 
50 live births (8 prem), 6 SA, 9 
TOP 
2 LTF, No data (37) 
3 minor anomalies (PFO+PDA, talipes varus, nasal 
deformity), 1 pre-eclampsia.   
1 premature infant developed foetal distress during 
labour, eventually resolved. 
Total pregnancies: 148                                                                                                                                                                  91 live births, 10 SA, 9 TOPs, 2 LTF, 37 no data 
In utero exposure to dopamine agonists 
Case reports: 9 studies 
10 pregnancies 10 PD PRAM (3),  
PER (1),  
CAB (2),  







29-36+ 11 live births (4 prem) 1 placental abruption, VSD in 1 twin, 1 neonate 
seizure 1 hr post-partum. 
Large case series and observational studies: 3 studies 
151 
pregnancies 
1 DRD, 20 RLS, 13 
PD 
117 no data 
BROM (20) 
PRAM (84) 






No data  
8-6 
No data  
No data  
100-300 
3-36+ 4 SA, 1 TOP, 31 live births (6 
prem) inc 2 pairs of twins.  
1 subsequent neonatal death 
due to liver enzyme deficiency. 
1 neonatal death.  
1 prem infant developed foetal distress during 
labour, eventually resolved.  
1 small for gestational age 
Total pregnancies: 161                                                                           42 live births (inc 3 pairs of twins) and 1 subsequent neonatal death, 4 SA, 1 TOP, 117 no data  
In utero exposure to anti-muscarinics 
Young et al 
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Case reports: 4 publications  
7 2 dystonia , 4 SCZ, 
1 PD 
TRI 2-50 36-42 6 healthy neonates.  
1 SA.  
 
In utero exposure to COMT inhibitors 
Case reports: 4 publications 
4 4 PD ENTA 200-700 12-36 5 live births  
(inc twins) 
1 neonate seizure 1 hr post-partum. PPROM in twin 
pregnancy with EMCS at 35 weeks. Small VSD in 1 
twin. 
In utero exposure to MAO inhibitors 
Case reports: 2 publications  
2 2 PD SELE 
 
7.5, 10 29-40 3 live births (inc twins) PPROM at 35 weeks with EMCS. Small VSD in one 
twin. 
 
Large case series: 1 publication  
7 7 PD RASA 1 4-36+ 7 live births (2 prem). 1 
neonatal death.  
1 Neonatal death of a twin due to liver enzyme 
deficiency. 
In utero exposure to DBS 
Case reports: 1 publication 
1 Dystonia   Used throughout 
gestation 
1 live birth  
Small case series: 1 publication 
4 Dystonia   Used throughout 
gestation 
4 live births Intrauterine growth retardation in one pregnancy  
Large case series: 2 publications 
18 PD, Dystonia, TS, 
OCD 
  Used throughout 
gestation 
18 live births (inc twins), 1 SA  
Legend: *36+ denotes levodopa exposure for full duration of pregnancy with term delivery, where exact gestational age at delivery is unavailable. 
AD= assisted delivery, APOM= Apomorphine, BROM= bromocriptine, CAB= cabergoline, DRD= Dopa-responsive Dystonia, ELCS= elective caesarean section, EMCS= emergency caesarean 
section, ENTA= entacapone, HPL= hyperprolactinaemia, LTF=lost to follow-up, MSA= multiple system atrophy, OCD=Obsessive-Compulsive Disorder,  P= Parkinsonism, PD= Parkinson’s 
disease, PDA=patent ductus arteriosus¸ PER= pergolide, PFO= patent foramen ovale, PRAM= pramipexole, PPROM= preterm premature rupture of membranes,  RLS= restless leg syndrome, 
ROP= ropinirole, ROT= rotigotine, SA= spontaneous abortion, SCZ= schizophrenia, SD= Segawa disease, SELE= selegiline, SGA= small for gestational age, TOP= termination of pregnancy, TRI= 
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Table 2: GRADE quality of evidence 
 
Drug 























Case reports: 22  
(32 pregnancies) 
Small case series: 3  
(12 pregnancies) 
Large case series: 4 
(25 pregnancies)  
Observational 
studies: 2  
(80 pregnancies)  
Predominantly case studies or case 
series; limited generalisability,  
 
Observational studies are based on 
data from drug registries; no control 
group for comparison.  
 
Many studies lack data re: drug dose 
and duration. 
Case report/series have 
largely consistent positive 
outcomes– no major foetal 
abnormalities reported 
with levodopa use.  
Outcome reasonably measure direct; foetal health 
and absence of malformation ~ safety of L-Dopa in 
pregnancy.  
 
> 51/143 patients treated for conditions other 
than PD- likely require lower doses of L-Dopa;  
 
Limited infant follow-up- adverse effects may not 
become apparent until later life 
Low– further research is 
likely to have an important 
impact on confidence in 















studies: 3  
(151 pregnancies) 
Case reports provide limited 




Case reports have largely 
consistent positive 
outcomes. No major foetal 
abnormalities reported. 
Outcome measure direct; foetal health and 
absence of malformation ~ safety of DA in 
pregnancy.  
 
Limited infant follow-up- adverse effects may not 
become apparent until later life. 
 
Very low –any estimate of 









case series: 4 
(7 pregnancies)  
  
Limited generalisability, cannot 
comment on causality. 
Too few studies to 
comment on consistency.  
 
Outcome measure direct; foetal health and 
absence of malformation ~ safety of anti-
muscarinics in pregnancy. Limited infant follow-up- 
adverse effects may not become apparent until 
later life. 
Very low- any estimate of 









case series: 4 (4 
pregnancies) 
Limited generalisability, cannot 
comment on causality. 
Too few studies to 
comment on consistency.  
 
Outcome measure direct; foetal health and 
absence of malformation ~ safety of COMT 
inhibitors in pregnancy. Limited infant follow-up- 
adverse effects may not become apparent until 
later life. 
Very low- any estimate of 




3 studies, 9 pregnancies.  
 
Case reports/small 
case series: 2 (2 
pregnancies) 
Large case series: 1 (7 
pregnancies) 
Limited generalisability, cannot 
comment on causality. 
Too few studies to 
comment on consistency.  
 
Outcome measure direct; foetal health and 
absence of malformation ~ safety of COMT 
inhibitors in pregnancy. Limited infant follow-up- 
adverse effects may not become apparent until 
later life. 
Very low- any estimate of 




4 studies, 23 pregnancies Case reports/small 
case series: 2 (5 
pregnancies) 
Large case series: 2 
(18 pregnancies) 
Limited generalisability, cannot 
comment on causality. 
Too few studies to 
comment on consistency.  
 
Outcome measure direct; foetal health and 
absence of malformation ~safety of DBS in 
pregnancy. Limited infant follow-up- adverse 
effects may not become apparent until later life. 
Very low- any estimate of 
safety is very uncertain 
Young et al 





Table 3. Neurologist (A) PD Nurse Specialist (B), Obstetrician (C), and patient (D) experiences of Parkinson’s Disease during pregnancy 
 
Case No. No of cases 


























provision of care 
a) Neurology informed 
of birth 











1 1 N - - No change - a) No change b) No change 
a) No change 







2 1 N 1st  No change  a) No change b) No change 
a) No change 







3 5 Y 1st 
Levodopa alone 




Return to usual 
regimen 
a) Generally worse 
b) 1 patient 
became depressed 






b) Yes (2 cases), No 
(3 cases) 
a) Yes 
b) Yes (2 cases) 
4 1 Y 1st  No change No change a) No change b) No change 
a) No change 






















b) No change 
a) Bradykinesia 
improved 







7 1 N 1st Levodopa Initially stopped, re-started. No change 
a) Worse without 
medication 
b) No change 
a) No change 







8 1 N 1st - No change No change 
a) No change 
b) Psychiatric 
symptoms 
a) No change 







B. PD Nurse Specialists 
1 1 Y 1st All stopped except Sinemet 6.25mg tds No change N/A 
a) No change 
b) No change 
a) N/A 
b) N/A SA 12 weeks 
a) Yes 
b)  - 
a) – 
b) N/A 
2 2 N 2nd Madopar 100/25 tds No change No change a) No change b) No change 
a) No change  
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a) No change  










b)  Joint review with 
midwife. Found 
midwife 
disinterested in birth 
plan. 
a) No  
b) No 










a) No change 
b) No change 
a) No change  




b)  No 
a) Yes  
b) Yes 
5 1 N 1st Dopamine agonist withheld. No change. Nil 
a) Bradykinesia, b) 
Fatigue. 
a) No change 



















Change to regular 
schedule of antenatal 
obstetric care 
Joint obstetric-neurology antenatal review 
a) Joint review undertaken 
b) Would joint review be helpful? 
Obstetric outcome 
Immediate post-partum care 
a) Inpatient neuro review  
b) Breastfeeding 





1 2 Pre-conception 1st 3-4 times 
More frequent 
antenatal clinic review 
a) Yes, b) Yes; ‘spare the women additional trips to 
hospital’ 
Live births, VD.  
No complications a)No, b)Unable, c) <3 days 










Increased visits, serial 
growth monitoring 
 
a) No, b) Yes; ‘allow discussion between obstetrics and 
neurology’ 
Live births, VD.  
No complications a) Yes, b) –  c) 4 days 
a) No outpatient 
obstetric review 
 
D. Women diagnosed with PD 
Case No. Patient demographic 
Pregnancy management 




a) Provision of antenatal care 
b) Frequency of antenatal neurology 
review 
Support and information 
a) Level of support from healthcare team, 
b) Provision of information during 
pregnancy 
Post-partum 
a) Breastfeeding, b) Attendance at 
mother and baby groups, c) Attendance 





G1P1, FH - 
a) No change, Levodopa/carbidopa 
during pregnancy  b) No change.  Live birth. EMCS, 37 weeks. a) Consultant-led, b) No change a) Well-supported, b) Inadequate 
a) Breastfed for 8 weeks, b) Attended , c) 




G2P2, FH + 
a) No change. Cannot recall for 1st 
pregnancy. Requip XL in 2nd pregnancy, b) 
General worsening of motor symptoms. 
Live birth.  
Live birth. VD, 36 weeks.  
 
a) Consultant-led, b) No change (6 
monthly) a) Well-supported, b) Adequate 
a) Not breastfed, b) Attended, c) Did not 




G2P?*, FH + 
a) Sinemet, Rasagiline, Ropinirole 
withheld. No medications taken. 
b) Improvement in motor symptoms, 
mood and energy. Most noticeable in 2nd 
trimester.  
Live birth. VD, 39 weeks. 
Admitted week 38. Neonatal 
hypoglycaemia post-partum; 
stayed 1 week in hospital.  
a) Consultant-led, b) No change (seen 
once during pregnancy) 
 
a) Poorly supported, b) Inadequate 
 
a) Breastfed for 1 week. Stopped to re-






G1P1, FH - 
a) None taken- no regular medication, b) 
PD presented during pregnancy and 
worsened in 2nd trimester. 
Live birth. EMCS, 35 weeks. 
HELLP syndrome. Infant in 
NICU for 24 hrs. 
a) Midwife-led, b) No formal diagnosis 
until post-partum a) Well-supported, b) Inadequate 
a) Not breastfed, b) Attended, c) Did not 
attend 
Young et al 






G2P1, FH - 
a) Cabergoline and orphenadrine 
withheld. Madopar 50/12.5mg during 
pregnancy b) Increased tremor. 
Stillbirth, 24 weeks  
Live birth. AD, full term 
a) Midwife-led, b) More frequent  
(seen 3 times) a) Unsure, b) Inadequate 
a) Not breastfed, b) Did not attend, c) Did 




G1P1, FH -  
 
 
a) No regular medication and none 
during pregnancy. PD diagnosed in early 
pregnancy.  
b) Worsening bradykinesia, UL tremor, 
dexterity, sialorrhoea. Most marked 3rd 
trimester 
Live birth. VD, 41 weeks. 
Maternal pyrexia post-
partum; given IV antibiotics 
overnight.   
a) Consultant-led  
b) First neurology consultation at 14 




a) Not breastfed.  
b) Attended  
c) Attended  





G1P1, FH - 
 
a) No regular medication. PD diagnosed 
post-partum.  
b) Worsening; tremor in 1st and 3rd 
trimesters. Micrographia. 
Live birth. AD, 40 weeks.  
Neonatal respiratory 
difficulties- infant in NICU for 
36 hrs. 
a) Consultant-led 
b) First neurology consultation at 12 
weeks; no regular neurology review 




a) Breastfed for 8 months. Stopped to 
start medication 
b) Attended  
c) Did not attend 
 
Legend: *outcome of second pregnancy not specified by respondent, G= gravidity, P= parity, eg. G1P1 = gravida 1, para 1, AD= Assisted 
delivery, EMCS= emergency caesarean section, FH= family history, HELLP syndrome= haemolysis, elevated liver enzymes, low platelets 





MEDLINE & Web of 
Science Database Search
(March 1985-June 2018, 































excluded as not 
considered 
relevant 
Number of articles 
identified from the 
reference list of 
screened articles
Levodopa – 31 publications – 148 pregnancies
Dopamine agonists – 12 publications – 161 pregnancies
Anti-muscarinic treatment – 4 publications – 4 pregnancies
COMT treatment – 4 publications – 4 pregnancies
MAOI treatment – 3 publications – 9 pregnancies
DBS treatment – 4 publications – 23 pregnancies
30 Case 
Reports
4 Small Case 
Series (n<5)
7 larger case 
series/cohort 
study (n>5)




Supplementary Table 1: Details of publications identified in Systematic Literature Review 
 
Author Year of 
publication 







Allain, H. et al. (1) 1989 1(1) PD Levodopa   
Asha, B. et al. (2) 
 
2010 1(1) PD Levodopa   
Ball, M. C. et al. (3) 
 
1995 1(1) P Levodopa  AD- delayed 2nd stage. No 
complications. 
Basile, S. et al. (4) 2017 1(1) PD Levodopa   
Campos-Sousa, R. N. 
et al (5) 
2008 1(8) PD Levodopa   
Cook, D. G. et al. (6) 1985 2(3) PD Levodopa   
De Mari, M. et al. (7) 2002 1(1) PD Levodopa   
Dostal, M. et al. (8) 2013 42(43) PD, RLS, SD, 
DRD, Suicide 
attempt  
Levodopa  3 SA. 7 pre-term deliveries. 3 
minor anomalies (PFO+PDA, 
talipes varus, nasal deformity). 
Golbe, L. I. (9) 1987 5(6) PD Levodopa 1 pre-eclampsia  
Ha, D. E. et al. (10) 2007 1(1) PD Levodopa  Pre-term delivery. PPROM at 26 
and 31 weeks with EMCS at 32 
weeks  
 
Hagell, P. et al. (11) 1998 1(1) PD Levodopa   
Jacquemard, F. et al. 
(12) 
1990 1(1) PD Levodopa   
Kallen, B. et al. (13) 2013 37(37) -  Levodopa   
Kanzato, N. et al. (14) 2006 1(1) PD Levodopa   
Kupsch, A. et al. (15) 1998 1(1) PD Levodopa   
Lindh, J. (16) 2007 1(1) PD Levodopa  Neonate seizure 1 hour post-
partum.  
Nomoto, M. et al. 
(17) 
1997 1(3) DRD Levodopa  SA at 6 and 12 weeks.  
Nygaard, T. G. et al. 
(18) 
1991 3(3) DRD Levodopa   
Routiot, T. et al. (19) 2000 1(1) PD Levodopa   
Scott, M. et al. (20) 2005 1(2) PD Levodopa  Pre-term delivery by EMCS- 
placental abruption at 32 
weeks   
 
Scelzo, E. et al. (21) 2015 3(6) PD Levodopa  2 SA 
Serikawa, T. et al. 
(22) 
2011 1 (1,twins) PD Levodopa  Pre-term delivery by EMCS- 
PPROM at 35 weeks. Small VSD 
in one twin.  
Shulman, L. M. et al. 
(23) 
2000 1(1) PD Levodopa   
Thulin, P. C. et al. 
(24) 
1998 1(1) PD Levodopa   
Tüfekçioǧlu, Z. et al. 
(25) 
2018 5(5) PD Levodopa  1 pre-term delivery by CS at 35 
weeks, infant developed foetal 
distress during labour, 
eventually resolved.  
von Graevenitz, K. S. 
et al. (26) 
1996 6(6) -  Levodopa  1 SA 
Ward, V. D. (27) 2018 1(1) PD Levodopa   
Watanabe, T. et al. 
(28) 
2009 6(8) SD Levodopa  2 SA 
Watanabe, T. et al. 
(29) 
2012 1(1) SD Levodopa   
Zhu, L. et al. (30) 2011 1(1) MSA Levodopa   
Zlotnik, Y. et al. (31) 2014 1(1) PD Levodopa Faltering growth at 13 months 
post-partum.  
Dopamine agonists  
Asha, B. et al. (2) 2010 1(1) PD ROP  
Benbir, G. et al. (32) 2014 1(1) PD PRAM Premature delivery at 35 
weeks.  
Benito-León, J. et al. 
(33) 
2001 1(1) PD BROM  
De Mari, M. et al. (7) 2002 1(1) PD PER  
Dostal, M. et al. (8) 2013 21(21,twins) RLS, SD PRAM, ROT, 
ROP 
3 SA, 3 premature deliveries, 1 
SGA 
Kallen, B. et al. (13) 2013 117(117) - BROM, PRAM, 
APOM, CAB 
 
Lamichhane, D. et al. 
(34) 
2014 1(1) PD PRAM  
Lindh, J. (16) 2007 1(1) PD BROM Neonate seizure 1 hour post-
partum  
 
Mucchiut, M. (35) 
 
2004 1(1) PD PRAM  
Scott, M. et al. (20) 2005 1(2) PD CAB Pre-term delivery at 32 weeks 
by EMCS for placental 
abruption.  
Serikawa, T. et al. 
(22) 
2011 1(1, twins) PD ROP Pre-term delivery by EMCS at 
35 weeks for PPROM. Small 
VSD in one twin. 
Tüfekçioǧlu, Z. et al. 
(25) 
 
2018 12(13, twins) PD PRAM, PIRI, 
ROP 
1 SA, 3 premature deliveries. 
Neonatal in 1 twin death due 
to liver enzyme deficiency.  
1 prem infant developed 
foetal distress during labour, 
eventually resolved. 
Anti-muscarinics  
Goyal, S. et al.  (36) 2017 1(1)  SCZ TRI  
Mendhekar, D. N. et 
al. (37) 
2011 1(3) SCZ TRI  
Robottom, B. J. et al.  
(38) 
 
2011 1(2) Dystonia  TRI  
Scelzo, E. et al. (21) 2015 1(1) PD TRI SA 
COMT inhibitors  
Basile, S. et al. (4) 2017 1(1) PD ENTA  
Lindh, J. (16) 
 
2007 1(1) PD ENTA 
 
Neonate seizure 1 hour post-
partum.  
 
Serikawa, T. et al. 
(22) 
 
2011 1(1, twins) PD ENTA Pre-term delivery by EMCS at 
35 weeks due to PPROM. 
Small VSD in one twin.  
 
Tüfekçioǧlu, Z. et al. 
(25) 
 
2018 1(1) PD  ENTA  
MOA inhibitors  
Kupsch, A. et al. (15) 1998 1(1) PD SELE  
Serikawa, T. et al.  
(22) 
 
2011 1(1, twins) PD SELE Pre-term delivery by EMCS at 
35 weeks due to PPROM. 
Small VSD in one twin. 
 
Tüfekçioǧlu, Z. et al. 
(25) 
 
2018 7(7, twins)  PD RASA 2 pre-term deliveries. 1 
neonatal death of a twin 





  indication  outcome 




Park H et al. (40) 
 
 










































3 PD, 5 
DYSTONIA, 
2 TS, 1 OCD 
 
DYSTONIA 
 7 live births, inc twins. 
1premature delivery at 35 
weeks. 
 
Live birth by ELCS at 38 
weeks.  
 
11 live births at term; 3 VD, 9 
CS. 1 SA.  
 
 
4 live births 
 
 
AD= assisted delivery, APOM= Apomorphine, BROM= bromocriptine, CAB= cabergoline, CS= 
caesarean section DRD= Dopa-responsive Dystonia, ELCS= elective caesarean section, EMCS= 
emergency caesarean section, ENTA= entacapone, HPL= hyperprolactinaemia, LTF=lost to follow-
up, MSA= multiple system atrophy, OCD=obsessive compulsive disorder, P= Parkinsonism, PD= 
Parkinson’s disease, PDA=patent ductus arteriosus¸ PER= pergolide, PFO= patent foramen ovale, 
PRAM= pramipexole, PPROM= preterm premature rupture of membranes,  RLS= restless leg 
syndrome, ROP= ropinirole, ROT= rotigotine, SA= spontaneous abortion, SCZ= schizophrenia, SD= 
Segawa disease, SELE= selegiline, SGA= small for gestational age, TOP= termination of pregnancy, 

















Supplementary Table 2: Summary of questionnaire free text responses 
A. Neurology suggested care   
Medication during pregnancy ‘I would review the potential of teratogenicity of the drugs the patient was taking and utilize the safest combination of medication for mother 
and child.’ N3  
 ‘I would make sure that all therapies are optimised, to ensure Mum is as fit as possible but would balance this with lowest drug doses to 
achieve this’ N17 
‘I would focus on treatment with L-dopa and try to minimise other drugs preferably from before conception to around 12 week.’ N1  
‘I probably would continue the levodopa, and if possible, use monotherapy.’ N18 
I would check with senior pharmacists, medical obstetricians and do a literature search for evidence on best practice.’ N8 
‘[manage] On an individual basis, adhering to guidelines where possible’ N31 
‘Consult the following sourced of information: 1) Movement Disorder Specialist, 2) Hospital Pharmacist, 3) the medical literature’ N29  
‘I suspect there isn’t a great deal of data. That said, methyl dopa is used for hypertension in pregnancy and I suspect the L-dopa preparations 
are the safest’ N33 
 
Communication  ‘Would check the safety of PD drugs on developing baby and discuss with patient.’ N16 
‘Early meeting to review meds, meeting during preg to discuss delivery and post-natal care’ N30 
‘Explain that pregnancy is generally safe in PD’ N9 
Antenatal review  ‘Referral to specialist md clinic.’ N25 
‘I would ensure regular PD nurse and movement disorders consultant review and liaison with Obstetrics’ N3  
‘speak with their midwife and a PD CNS’ N26 
‘close liaison with obstetrician and midwife.’ N30 
‘I would check with senior pharmacists’ N8  
‘I would seek specialist input from a Parkinson’s/movement disorders expert’ N35 
Delivery and post-partum care  ‘Ultimately, I would want to have a plan for the birth if it looks like it may be complicated, e.g. ensuring it’s at a site with neurology cover.’ 
N26 
‘meeting during preg to discuss delivery and post-natal care’ N30 
B. PD Nurse Specialist suggested care  
Use of medication during pregnancy ‘Read up on medications via Electronic Medicines Compendium and local Trust guidelines/NICE best practice’ PDNS 37 
‘I would gain more info re medication that can be taken during pregnancy’ PDNS 14  
‘check the BNF regarding medications’ PDNS 27 
‘I have no experience and with no guidelines, I would try and keep medication to a minimum.’ PDNS 12 
 ‘Discuss with patient need for medication decide if could wean off dopaminergic therapy if taking low doses.’ PDNS 8 
 ‘Minimise medication as much as possible. If possible, remove all but levodopa’ PDNS 11 
‘Maintain stability, don't introduce any new treatments’ PDNS 31  
Multi-disciplinary working  ‘Liaise closely with Neurologist in our service who specialises in maternal medicine and a midwife who works with him…Work with speciality 
midwife re symptom management.’ PDNS 7 
‘In very close coordination with the patient, Consultant and GP’. PDNS 36 
‘As this is an area where I have no previous experience, I would liaise closely with the patient’s neurologist in order to develop a management 
plan with an agreed plan of ongoing monitoring.’ PDNS 15 
‘MDT approach to include Neurologists midwives, physiotherapy. Closer monitoring’ PDNS 23  
‘Having no experience, I would d be asking other PDNS for information’ PDNS 9  
‘Ask local group/ PDNSA for any experience/advice.’ PDNS 10 
‘I would contact colleagues who've had experience in this area and would be guided by their knowledge & experience’ PDNS 20  
‘Same as epilepsy. In the same manner my colleague does with patients with epilepsy who are pregnant.’ PDNS 6  
‘In close collaboration with their consultant neurologist and obstetrician.’ PDNS 16 
‘‘MDT approach’ PDNS 32 
‘Liaise with obstetric team.’ PDNS 8 
‘I would seek advice from multi-professional team and Neurologist.’ PDNS 37 
‘see if I could arrange joint working with a midwife’ PDNS 27 
‘Jointly with consultant. Be available to midwife to discuss’ PDNS 34 
‘Liaise with midwives.’ PDNS 38 
‘Obs involvement. Positively and supportively but with caution and close involvement of the obstetrician.’ PDNS 2  
‘I would look for as much information as possible e.g. on-line, journals, Parkinson's UK, other Parkinson's Nurses, on-line forum on the 
members area of Parkinson's Disease Nurse Specialist Association website, the patient's Parkinson's Consultant and Consultant Obstetrician, 
pharmacists.’ PDNS 3 
‘liaise with maternity team’ PDNS18 
‘Liaise with the obstetricians.’ PDNS 30 
Antenatal review  ‘Emphasise their open access to the service.’ PDNS 10 
‘Increase visits’ PDNS 18 
‘Closer monitoring’ PDNS 23  
‘Frequent reviews’. ‘Ask patient to keep symptoms diary’ PDNS 34 
C. Obstetrics suggested care    
Reasons for obstetric-led antenatal 
review  
‘with medication involved’ O6 
‘would want to ensure no decline during pregnancy’ O7 
‘given the unknown challenges and the need for a multidisciplinary approach’ O4  
‘Multidisciplinary team including a medical midwife, obstetric physician and MFM obstetrician with advice from the patients primary 
neurologist’ O12 
‘extra reassurance, fetal growth scans, MDT input with close liaison between Obs, neuro and anaesthetics, consideration of VTE prophylaxis 
etc’ O10 
‘Could be either - if early in disease process and no concerns, MLC might be best. CLC would ensure liaison with neurology colleagues, contact 
with nurse specialist and joint planning for delivery and postnatal’ O14 
‘would be easier to arrange follow-ups and implement any management plan’ O15 
Schedule of antenatal care   ‘as standard regimen, more frequently if progressive Parkinson’s disease activity’ O4 
‘standard obstetric care’ O6  
‘care as usual and more often based on complaints’ O5 
‘Pre-pregnancy counselling’ O12 
‘[appointments] Ideally coinciding with fetal growth scans.’ O10 
‘Regular monthly joint clinic’ O2 
Frequency of discussion with neurology  
team 
‘Regular monthly joint clinic and contact if any concerns’ O2 
‘Once or twice if no problems, more frequently if progressive Parkinson’s disease activity’ O4 
‘Once in the beginning of pregnancy and in the third trimester, also with anaesthetist’ O6 
‘At least each trimester.’ O10 
‘General planning discussion preferably pre-pregnancy, otherwise when booking with our clinic. Discussion with neurology after that only if 
needed or if altering medications’ O12 
‘Pre-conception .At booking . With change’ O13 
‘At booking, following any significant clinical change or change of medication, prior to delivery for planning’ O15 
Suggested delivery  ‘Not [c-section] unless there were other obstetric indications’ O12 
‘No [c-section]. I would reserve section for Obstetric reasons only. There are pros and cons of this, but, as with many medical Obs patients, we 
would encourage an early epidural, offer induction of labour at term (to give some ‘predictability’) and have an honest dialogue with the pt and 
whole MDT about the birth plan.’ O10 
‘Not routinely - there can be allowances made to minimise active (pushing) phase’ O15 
Post-partum care  ‘Depending of level of disability likely to need longer postnatal hospital stay and occupational therapy input around infant cares’ O12 
‘Monitor patient in HDU on the delivery suite for 24 hours postpartum. Be aware of potential for worsening on symptoms. Neurology review 
within 24 hours of delivery.’ O10 
‘ensure support from midwives’ O7 
‘Neurology follow up’ O14 
D. Midwifery suggested care  
Antenatal review  ‘Obstetric referral, Obstetric led care’ M2  
‘During pregnancy I would expect the woman to be placed under consultant led care with multi-disciplinary input…The woman would also 
see her midwife in community to provide normal antenatal care, monitoring, and emotional support throughout the pregnancy.’ 
‘Physiotherapy input to reduce the risk of falls and therefore injury to the woman and fetus.’ ‘There may also be serial ultrasound scans to 
monitor fetal growth and development.’ M3 
‘I would mainly think about how well she is able to access antenatal care, possible home midwife visits maybe more appropriate than possible 
long waits in clinics.’ ‘Perhaps seeing a physio would help with balance issues (also antenatally).’ M1 
‘liaise with other health professional involved in current care. consultant led. foetal medicine early pregnancy. care physio referral. 






‘Booking and antenatal care: refer to consultant led care, refer for a specialist nurse who deals with Parkinson’s , more antenatal 
appointment due to ?higher risk in pregnancy.’ M15 
‘assess mobility. consider serial growth scans due to medication’ M16 
‘that the woman is seen by her medical, obstetric & anaesthetic team to ensure that a multi disciplinary care plan for her antenatal care & 




Intrapartum care    ‘In labour, my train of thought is that she might tire easily if her Parkinson’s is severe, so advising her periods of rest as well as helping her to 
be somewhat mobile during labour.’  M1 
‘During labour care and the woman might have regular mobility checks to reduce the risk of falls whilst also recommending active labour 
where possible.’ M3 
‘physical support in labour’ M5 
‘Labour care’ M10 
‘delivery in an Obstetric unit or Midwifery led unit alongside an Obstetric unit.’ M2 
‘The obstetricians would decide whether an early induction of labour 37-39 weeks gestation would be of benefit to ensure the best outcome.’ 
M3 
Post-partum care  ‘Postnatal period I’d like so support her with how she handles her baby and how she can manage this with her movements.’ M1 
‘I also think it would be a good idea during pregnancy for the woman to have advise on caring for a newborn with her condition.’ M3 
‘assessment of adapted care for baby following delivery’ M5 
‘postnatal care afterwards’ M8 
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